---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-273278"
form_type: "8-K"
ticker: "WVE"
cik: "0001631574"
company_name: "Wave Life Sciences Ltd."
filed_at: "2025-11-10T23:59:59+00:00"
generated_at: "2026-05-16T22:25:05.007961+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Wave Life Sciences Q3 net loss $53.9M; obesity drug WVE-007 shows 85% Activin E reduction

## Summary
- WVE-007: dose-dependent Activin E reduction up to 85% in INLIGHT; sustained through 6 months at lowest dose; supports once/twice yearly dosing.
- WVE-006 recapitulated MZ phenotype: AAT >20 µM during acute phase, wild-type M-AAT 64% of serum AAT, Z-AAT reduced 60% in RestorAATion-2.
- Cash $196.2M at Sept 30; $72.1M post-quarter from ATM and GSK milestones extend runway into Q2 2027.
- Net loss $53.9M vs $61.8M prior year; revenue $7.6M vs ($7.7M); R&D $45.9M, G&A $18.1M.
- Milestones: INLIGHT body weight data Q4 2025; NDA for WVE-N531 in 2026; IND for WVE-003 Phase 2/3 H2 2025.

## SEC filing metadata
- accession: 0001193125-25-273278
- form_type: 8-K
- ticker: WVE
- cik: 0001631574
- company_name: Wave Life Sciences Ltd.
- filed_at: 2025-11-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1631574/000119312525273278/0001193125-25-273278-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1631574/000119312525273278/d44041d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-273278
- JSON: https://secwatch.observer/filing/0001193125-25-273278.json
- Plain text: https://secwatch.observer/filing/0001193125-25-273278.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.